ClinicalTrials.gg
CompletedNCT00913432Updated Dec 13, 2018

Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis

A Phase 2 interventional study of masitinib and masitinib in Rheumatoid Arthritis, sponsored by AB Science. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-13.

Sponsored by AB Science · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A 12-week with possible extension, phase II study to compare efficacy and safety of masitinib at 3 and 6 mg/kg/day in combination with methotrexate, in treatment of patients with active rheumatoid arthritis refractory to standard treatments.

02

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • rheumatoid arthritis
  • methotrexate
  • DMARD
  • c-kit inhibitor
03

In context

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

This study's enrollment of 20 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.

Browse Arthritis, Rheumatoid studies →

Lead sponsor

AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Disease duration of at least 6 months Meet American College of Rheumatology (ACR) criteria for RA.
  2. ACR functional class I-III
  3. Have active RA
  4. Failed (defined as active RA with stable dose during 3 months) i. methotrexate or ii. any DMARD including anti TNF alpha if patients previously failed methotrexate or iii. methotrexate in combination with any DMARD including anti TNF alpha

Exclusion criteria

Exclusion Criteria:

  1. Patient had a major surgery within 2 weeks prior to study entry.
  2. \< 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    masitinib 3 mg

    masitinib 3 mg/kg/day

    Drug: masitinib

  • Experimental
    masitinib 6 mg

    masitinib 6 mg/kg/day

    Drug: masitinib

Interventions

  • 3 mg/kg/day oral route

    Also known as: AB1010

  • masitinib 6 mg/kg/day oral route

    Also known as: AB1010

06

What researchers measure

Primary outcomes

  1. American College of Rheumatology Score 50

    Time frame: week 12

Secondary outcomes

  1. DAS28

    Time frame: week 4, 8 and 12

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Jun 2009 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2009
First posted
Jun 4, 2009
Start
Mar 2007
Primary completionActual
Jun 2009
CompletionActual
Sep 2010
Last update
Dec 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00913432
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Jun 4, 2009
Start date
Mar 2007
Primary completion
Jun 2009
Completion
Sep 2010
Last update
Dec 13, 2018

Study contacts

Jacques Tebib, MD, PhD
principal investigator · CHU de Lyon Sud

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion